Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
“CAR T’s biggest hurdle: solving the toxicity problem
CAR T-cell therapy has redefined cancer care—saving lives by engineering a patient’s own T cells to recognize and destroy tumors. But toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain major barriers.
Up to 95% of patients experience CRS and nearly half develop ICANS—complications that are not only life-threatening but also limit scalability, access, and outpatient delivery of CAR T.
CytoAgents, Inc is leading efforts to change this with CTO1681, an oral small molecule designed to prevent CRS and ICANS. Now in Phase Ib/IIa trials, this approach could unlock safer, more accessible CAR T—helping shift treatment into the outpatient and community setting.
The future of CAR T will depend not only on its curative potential, but on making these therapies safe, scalable, and sustainable.”
More posts featuring Yan Leyfman on OncoDaily.